{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:36:21Z","timestamp":1761748581781,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1604,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.acvd.2009.02.007","type":"journal-article","created":{"date-parts":[[2009,4,7]],"date-time":"2009-04-07T04:59:54Z","timestamp":1239080394000},"page":"327-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?"],"prefix":"10.1016","volume":"102","author":[{"given":"Nadia","family":"Rosencher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenn","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Arnaout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2009.02.007_bib1","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2009.02.007_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0265021505002164","article-title":"Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines","volume":"23","author":"Samama","year":"2006","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.acvd.2009.02.007_bib3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1055\/s-0037-1613733","article-title":"Significantly lower need for blood transfusions associated with postoperatively initiated subcutaneous melagatran\/oral ximelagatran compared with enoxaparin","volume":"92","author":"Eriksson","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2009.02.007_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood.V108.11.573.573","article-title":"A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (the RE-MODEL trial)","author":"Eriksson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.acvd.2009.02.007_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2009.02.007_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.acvd.2009.02.007_bib7","unstructured":"Caprini JA, Hwang SJ, Hantel S, et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopedic surgery. J Thromb Haemost 2007;5(Suppl. 2) [Abstr O-W-050]."},{"key":"10.1016\/j.acvd.2009.02.007_bib8","doi-asserted-by":"crossref","unstructured":"Dahl O, Kurth AA, Rosencher N, et al. 150mg Dabigatran etexilate once daily has a good safety profile and comparable efficacy to enoxaparin for primary prevention of venous thromboembolism after total knee or hip replacement surgery in patients older than 75 years or with reduced renal function. Blood (ASH Annual Meeting Abstracts) 2008;112 [Abstract 437].","DOI":"10.1182\/blood.V112.11.437.437"},{"key":"10.1016\/j.acvd.2009.02.007_bib9","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.02.007_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2009.02.007_bib11","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2009.02.007_bib12","doi-asserted-by":"crossref","unstructured":"Turpie AGG, Lassen MR, Kakkar AK, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism, death, and bleeding. Blood (ASH Annual Meeting Abstracts) 2008;8:112 [Abstract 36].","DOI":"10.1182\/blood.V112.11.36.36"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213609000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213609000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:36:20Z","timestamp":1761744980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213609000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1875213609000527"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2009.02.007","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2009.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}